Observes brigatinib use and lung side effects in Japanese people with lung cancer
Studies brigatinib tablets for lung cancer in Japanese patients, watching for lung side effects.
Plain-language title generated from the registry record
Registry title: Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer
Key facts
- Where
- Tokyo, JapanSee the site
Where in Japan
- TokyoTokyo, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Takeda
- Trial code
- NCT05100069
- Record updated
- 17 March 2026
- Original description
This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.Read full original descriptionShow less
General Use-results Survey of Alunbrig Tablets "Non-small Cell Lung Cancer"
This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.
The main aim of the study is to check for side effects related to lung disease from Brigatinib. During the study, participants with non-small cell lung cancer will take Brigatinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Brigatinib for 1 year.